Prestige Consumer Healthcare Inc. (PBH): M&A transaction — Prestige closes $1.045B acquisition of Breathe Right brand from Foundation

Prestige Consumer Healthcare Inc.

Purchase price $1.045B cash; net of $150M tax benefits, effective cost ~$900M.
Financed via new Term Loan B of $1.045B (Term SOFR + 2.00%) and cash on hand.
ABL facility amended and upsized to $225M with 5-year maturity from closing.
Breathe Right becomes Prestige's largest brand, entering a new nasal strip category.
LaCorium acquisition expected Q2 FY27; up to $95M additional term loans available.

item 1.01 item 2.01 item 2.03 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Prestige Consumer Healthcare Inc. amended revolving credit of $225 million with Citibank, N.A., as the administrative agent maturing the date that is five years from the Closing Date.

Instrument: revolving credit
Principal: $225 million
Counterparty: Citibank, N.A., as the administrative agent
Maturity: the date that is five years from the Closing Date
Event: amendment

Exact text from the filing

the ABL Amendment (i) increased the aggregate commitments under the ABL Credit Facility to $225 million and (ii) extended the maturity date of the ABL Credit Agreement to the date that is five years from the Closing Date

View on SEC.gov

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Prestige Consumer Healthcare Inc. incurred credit facility of $1.045 billion with Citibank, N.A. as administrative agent at Term SOFR plus 2.00%.

Instrument: credit facility
Principal: $1.045 billion
Counterparty: Citibank, N.A. as administrative agent
Rate: Term SOFR plus 2.00%
Event: incurrence

Exact text from the filing

Proceeds of term loans borrowed under the Term Loan Credit Agreement in the amount of $1.045 billion were used to finance the Transactions (as defined below) that occurred on the Closing Date

View on SEC.gov

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Prestige Consumer Healthcare Inc. completed an acquisition involving Foundation Consumer Brands, LLC and certain of its affiliates for $1.045 billion in cash (closed 2026-06-12).

Action: acquisition
Counterparty: Foundation Consumer Brands, LLC and certain of its affiliates
Consideration: $1.045 billion in cash
Closing: 2026-06-12

Exact text from the filing

On June 12, 2026, the Borrower and Medtech Products Inc. (“MedTech”), a wholly-owned subsidiary of the Company, completed the previously announced acquisition of Breathe Right® and certain other brands (the “Breathe Right Business”) from Foundation Consumer Brands, LLC and certain of its affiliates, pursuant to an Asset Purchase Agreement, dated as of March 19, 2026 (the “Purchase Agreement”), for a purchase price of $1.045 billion in cash (the “Transaction”).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Prestige Consumer Healthcare Inc. entered into Term Loan Credit Agreement with Citibank, N.A., Barclays Bank PLC, Morgan Stanley Senior Funding Inc., Goldman Sachs Bank USA and RBC Capital Markets valued at $1.045 billion (effective 2026-06-12).

Action: entry
Agreement: credit facility
Counterparty: Citibank, N.A., Barclays Bank PLC, Morgan Stanley Senior Funding Inc., Goldman Sachs Bank USA and RBC Capital Markets
Value: $1.045 billion
Effective: 2026-06-12

Exact text from the filing

On June 12, 2026 (the "Closing Date"), Prestige Consumer Healthcare Inc. (the "Company") and its wholly-owned subsidiary, Prestige Brands, Inc. (the "Borrower"), entered into that certain Term Loan Credit Agreement (the "Term Loan Credit Agreement") by and among the Company, the Borrower, certain other subsidiaries of the Company as guarantors, Citibank, N.A. as administrative agent, the lenders party thereto and Citibank, N.A., Barclays Bank PLC, Morgan Stanley Senior Funding Inc., Goldman Sachs Bank USA and RBC Capital Markets, as joint lead arrangers and joint bookrunners.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Prestige Consumer Healthcare Inc. amended Amendment No. 10 with Citibank, N.A. valued at $225 million (effective 2026-06-12).

Action: amendment
Agreement: credit facility
Counterparty: Citibank, N.A.
Value: $225 million
Effective: 2026-06-12

Exact text from the filing

the Company and the Borrower entered into Amendment No. 10 (the "ABL Amendment") to the credit agreement governing the Company's asset-based revolving line of credit (as amended, the "ABL Credit Agreement") originally entered into on January 31, 2012, by and among the Company, the Borrower, certain subsidiaries party thereto as guarantors, the lenders party thereto and Citibank, N.A., as the administrative agent.

View on SEC.gov

296 debt financings filed in the last 30 days. Browse all debt financings →

Prestige Consumer Healthcare Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-074259

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.